X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare TTK HEALTHCARE with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TTK HEALTHCARE vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TTK HEALTHCARE DISHMAN PHARMA TTK HEALTHCARE/
DISHMAN PHARMA
 
P/E (TTM) x 22.0 25.1 87.7% View Chart
P/BV x 7.4 3.3 221.1% View Chart
Dividend Yield % 0.4 0.7 59.1%  

Financials

 TTK HEALTHCARE   DISHMAN PHARMA
EQUITY SHARE DATA
    TTK HEALTHCARE
Mar-14
DISHMAN PHARMA
Mar-16
TTK HEALTHCARE/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs663374 177.2%   
Low Rs399129 309.5%   
Sales per share (Unadj.) Rs535.6197.8 270.8%  
Earnings per share (Unadj.) Rs15.921.2 75.2%  
Cash flow per share (Unadj.) Rs20.034.7 57.7%  
Dividends per share (Unadj.) Rs4.002.00 200.0%  
Dividend yield (eoy) %0.80.8 94.7%  
Book value per share (Unadj.) Rs137.6179.9 76.5%  
Shares outstanding (eoy) m7.7780.69 9.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.01.3 78.0%   
Avg P/E ratio x33.311.9 280.7%  
P/CF ratio (eoy) x26.57.2 366.0%  
Price / Book Value ratio x3.91.4 275.9%  
Dividend payout %25.19.4 266.0%   
Avg Mkt Cap Rs m4,12720,306 20.3%   
No. of employees `0001.70.8 206.0%   
Total wages/salary Rs m6075,355 11.3%   
Avg. sales/employee Rs Th2,436.719,252.7 12.7%   
Avg. wages/employee Rs Th355.26,459.5 5.5%   
Avg. net profit/employee Rs Th72.52,064.1 3.5%   
INCOME DATA
Net Sales Rs m4,16215,961 26.1%  
Other income Rs m61265 23.1%   
Total revenues Rs m4,22316,226 26.0%   
Gross profit Rs m1974,103 4.8%  
Depreciation Rs m321,091 2.9%   
Interest Rs m30944 3.2%   
Profit before tax Rs m1972,334 8.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m73624 11.7%   
Profit after tax Rs m1241,711 7.2%  
Gross profit margin %4.725.7 18.4%  
Effective tax rate %37.026.7 138.5%   
Net profit margin %3.010.7 27.8%  
BALANCE SHEET DATA
Current assets Rs m1,62911,018 14.8%   
Current liabilities Rs m1,0589,517 11.1%   
Net working cap to sales %13.79.4 145.9%  
Current ratio x1.51.2 133.0%  
Inventory Days Days30110 27.0%  
Debtors Days Days3435 96.4%  
Net fixed assets Rs m55616,304 3.4%   
Share capital Rs m78161 48.1%   
"Free" reserves Rs m87812,907 6.8%   
Net worth Rs m1,06914,516 7.4%   
Long term debt Rs m1594,189 3.8%   
Total assets Rs m2,39929,805 8.1%  
Interest coverage x7.63.5 218.3%   
Debt to equity ratio x0.10.3 51.4%  
Sales to assets ratio x1.70.5 323.9%   
Return on assets %6.48.9 71.9%  
Return on equity %11.611.8 98.3%  
Return on capital %18.517.5 105.3%  
Exports to sales %0.824.8 3.2%   
Imports to sales %1.43.7 37.5%   
Exports (fob) Rs m333,956 0.8%   
Imports (cif) Rs m58596 9.8%   
Fx inflow Rs m334,952 0.7%   
Fx outflow Rs m63697 9.1%   
Net fx Rs m-304,255 -0.7%   
CASH FLOW
From Operations Rs m1272,786 4.5%  
From Investments Rs m-146-1,529 9.5%  
From Financial Activity Rs m22-941 -2.3%  
Net Cashflow Rs m3316 0.8%  

Share Holding

Indian Promoters % 65.4 61.4 106.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 3.7 100.0%  
FIIs % 5.2 12.7 40.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.8 22.1 116.7%  
Shareholders   12,723 46,261 27.5%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TTK HEALTHCARE With:   DR. REDDYS LAB  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare TTK HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (4QFY18); Net Profit Up 43.1% (Quarterly Result Update)

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, TTK HEALTHCARE has posted a net profit of Rs 80 m (up 43.1% YoY). Sales on the other hand came in at Rs 1 bn (up 21.4% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TTK HEALTHCARE SHARE PRICE


Sep 26, 2018 (Close)

TRACK TTK HEALTHCARE

  • Track your investment in TTK HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TTK HEALTHCARE

TTK HEALTHCARE - PLETHICO PHARMA COMPARISON

COMPARE TTK HEALTHCARE WITH

MARKET STATS